Combined JAK- and TNFα-targeting in severe steroid-refractory graft-versus-host disease in children - Scorecard - MDSpire

Combined JAK- and TNFα-targeting in severe steroid-refractory graft-versus-host disease in children

  • By

  • Manon Queudeville

  • Jaspar Kloehn

  • Ysabel Alessa Schwietzer

  • Kai Lehmberg

  • Johanna Schrum

  • Ingo Müller

  • June 12, 2026

  • 0 min

Share

Clinical Scorecard: Dual Targeting of JAK and TNFα in Pediatric Patients with Severe Steroid-Resistant Graft-versus-Host Disease

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingSpecify if the study was conducted in a single center or multiple centers.

Key Highlights

  • add_source

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • p
      • a
      • r
      • a
      • m
      • e
      • t
      • e
      • r
      • s
      • f
      • o
      • r
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • a
      • d
      • v
      • e
      • r
      • s
      • e
      • e
      • v
      • e
      • n
      • t
      • s
      • r
      • e
      • l
      • a
      • t
      • e
      • d
      • t
      • o
      • r
      • u
      • x
      • o
      • l
      • i
      • t
      • i
      • n
      • i
      • b
      • .

      Risks

        Patient & Prescribing Data

        Include potential side effects and management strategies for combination therapy.

        Clinical Best Practices

        • add_patient_education

        Related Resources & Content

        Original Source(s)

        Combined JAK- and TNFα-targeting in severe steroid-refractory graft-versus-host disease in children

        • by Manon Queudeville, Jaspar Kloehn, Ysabel Alessa Schwietzer, Kai Lehmberg, Johanna Schrum, Ingo Müller

        • June 12, 2026

        Related Content

        Multimodal management of late-stage Bockenheimer disease complicated by severe anemia and coagulopathy: a case report

        Development and validation of a predictive model for chronic or persistent immune thrombocytopenia in children incorporating anti-glycoprotein IIb antibody: a retrospective cohort study utilizing LASSO regression and bootstrap stability analysis

        This Week’s CGT News: Novo’s Parkinson’s Pivot

        Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward

        • May 18, 2026

        • 7 min